Autolus Therapeutics (AUTL) to Release Earnings on Tuesday

Autolus Therapeutics (NASDAQ:AUTL) is set to post its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Autolus Therapeutics to post earnings of ($0.21) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Stock Up 0.9 %

AUTL traded up $0.03 during trading hours on Tuesday, hitting $3.37. 431,910 shares of the company’s stock were exchanged, compared to its average volume of 1,378,661. Autolus Therapeutics has a 1-year low of $3.06 and a 1-year high of $7.45. The stock’s 50-day moving average is $4.00 and its two-hundred day moving average is $4.03. The stock has a market cap of $896.72 million, a price-to-earnings ratio of -2.91 and a beta of 2.04. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.